These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 29088772)

  • 1. Vitamin D receptor-binding site variants affect prostate cancer progression.
    Lin VC; Huang SP; Ting HJ; Ma WL; Yu CC; Huang CY; Yin HL; Huang TY; Lee CH; Chang TY; Lu TL; Bao BY
    Oncotarget; 2017 Sep; 8(43):74119-74128. PubMed ID: 29088772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic variations in VDR associated with prostate cancer risk and progression in a Korean population.
    Oh JJ; Byun SS; Lee SE; Hong SK; Jeong CW; Kim D; Kim HJ; Myung SC
    Gene; 2014 Jan; 533(1):86-93. PubMed ID: 24120391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic polymorphisms in oestrogen receptor-binding sites affect clinical outcomes in patients with prostate cancer receiving androgen-deprivation therapy.
    Huang CN; Huang SP; Pao JB; Hour TC; Chang TY; Lan YH; Lu TL; Lee HZ; Juang SH; Wu PP; Huang CY; Hsieh CJ; Bao BY
    J Intern Med; 2012 May; 271(5):499-509. PubMed ID: 21880074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic variants in nuclear factor-kappa B binding sites are associated with clinical outcomes in prostate cancer patients.
    Huang SP; Lin VC; Lee YC; Yu CC; Huang CY; Chang TY; Lee HZ; Juang SH; Lu TL; Bao BY
    Eur J Cancer; 2013 Nov; 49(17):3729-37. PubMed ID: 23920401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive association analysis of the vitamin D pathway genes, VDR, CYP27B1, and CYP24A1, in prostate cancer.
    Holick CN; Stanford JL; Kwon EM; Ostrander EA; Nejentsev S; Peters U
    Cancer Epidemiol Biomarkers Prev; 2007 Oct; 16(10):1990-9. PubMed ID: 17932346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vitamin-D pathway genes and HIV-1 disease progression in injection drug users.
    Laplana M; Sánchez-de-la-Torre M; Puig T; Caruz A; Fibla J
    Gene; 2014 Jul; 545(1):163-9. PubMed ID: 24768180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic variations in TP53 binding sites are predictors of clinical outcomes in prostate cancer patients.
    Lin VC; Huang CY; Lee YC; Yu CC; Chang TY; Lu TL; Huang SP; Bao BY
    Arch Toxicol; 2014 Apr; 88(4):901-11. PubMed ID: 24448834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Seasonal and geographical variations in lung cancer prognosis in Norway. Does Vitamin D from the sun play a role?
    Porojnicu AC; Robsahm TE; Dahlback A; Berg JP; Christiani D; Bruland OS; Moan J
    Lung Cancer; 2007 Mar; 55(3):263-70. PubMed ID: 17207891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vitamin D receptor polymorphisms and breast cancer risk: results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium.
    McKay JD; McCullough ML; Ziegler RG; Kraft P; Saltzman BS; Riboli E; Barricarte A; Berg CD; Bergland G; Bingham S; Brustad M; Bueno-de-Mesquita HB; Burdette L; Buring J; Calle EE; Chanock SJ; Clavel-Chapelon F; Cox DG; Dossus L; Feigelson HS; Haiman CA; Hankinson SE; Hoover RN; Hunter DJ; Husing A; Kaaks R; Kolonel LN; Le Marchand L; Linseisen J; McCarty CA; Overvad K; Panico S; Purdue MP; Stram DO; Stevens VL; Trichopoulos D; Willett WC; Yuenger J; Thun MJ
    Cancer Epidemiol Biomarkers Prev; 2009 Jan; 18(1):297-305. PubMed ID: 19124512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer.
    Li H; Stampfer MJ; Hollis JB; Mucci LA; Gaziano JM; Hunter D; Giovannucci EL; Ma J
    PLoS Med; 2007 Mar; 4(3):e103. PubMed ID: 17388667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Altered SMRT levels disrupt vitamin D3 receptor signalling in prostate cancer cells.
    Khanim FL; Gommersall LM; Wood VH; Smith KL; Montalvo L; O'Neill LP; Xu Y; Peehl DM; Stewart PM; Turner BM; Campbell MJ
    Oncogene; 2004 Sep; 23(40):6712-25. PubMed ID: 15300237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of vitamin D receptor gene polymorphisms in the susceptibility to prostate cancer of a southern European population.
    Medeiros R; Morais A; Vasconcelos A; Costa S; Pinto D; Oliveira J; Lopes C
    J Hum Genet; 2002; 47(8):413-8. PubMed ID: 12181642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. VDR regulation of microRNA differs across prostate cell models suggesting extremely flexible control of transcription.
    Singh PK; Long MD; Battaglia S; Hu Q; Liu S; Sucheston-Campbell LE; Campbell MJ
    Epigenetics; 2015; 10(1):40-9. PubMed ID: 25494645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of vitamin D receptor as a potential prognostic factor and therapeutic target in pancreatic cancer.
    Wang K; Dong M; Sheng W; Liu Q; Yu D; Dong Q; Li Q; Wang J
    Histopathology; 2015 Sep; 67(3):386-97. PubMed ID: 25641222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IRX4 at 5p15 suppresses prostate cancer growth through the interaction with vitamin D receptor, conferring prostate cancer susceptibility.
    Nguyen HH; Takata R; Akamatsu S; Shigemizu D; Tsunoda T; Furihata M; Takahashi A; Kubo M; Kamatani N; Ogawa O; Fujioka T; Nakamura Y; Nakagawa H
    Hum Mol Genet; 2012 May; 21(9):2076-85. PubMed ID: 22323358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of proliferation and induction of apoptosis by 25-hydroxyvitamin D3-3beta-(2)-Bromoacetate, a nontoxic and vitamin D receptor-alkylating analog of 25-hydroxyvitamin D3 in prostate cancer cells.
    Swamy N; Chen TC; Peleg S; Dhawan P; Christakos S; Stewart LV; Weigel NL; Mehta RG; Holick MF; Ray R
    Clin Cancer Res; 2004 Dec; 10(23):8018-27. PubMed ID: 15585637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vitamin D receptor (VDR) gene polymorphisms and haplotypes, interactions with plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D, and prostate cancer risk.
    Mikhak B; Hunter DJ; Spiegelman D; Platz EA; Hollis BW; Giovannucci E
    Prostate; 2007 Jun; 67(9):911-23. PubMed ID: 17440943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic silencing of tumor suppressor candidate 3 confers adverse prognosis in early colorectal cancer.
    Burgermeister E; Höde P; Betge J; Gutting T; Merkel A; Wu W; Tänzer M; Mossner M; Nowak D; Magdeburg J; Rückert F; Sticht C; Breitkopf-Heinlein K; Schulte N; Härtel N; Belle S; Post S; Gaiser T; Heppner BI; Behrens HM; Röcken C; Ebert MPA
    Oncotarget; 2017 Oct; 8(49):84714-84728. PubMed ID: 29156678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased expression of corepressors in aggressive androgen-independent prostate cancer cells results in loss of 1alpha,25-dihydroxyvitamin D3 responsiveness.
    Ting HJ; Bao BY; Reeder JE; Messing EM; Lee YF
    Mol Cancer Res; 2007 Sep; 5(9):967-80. PubMed ID: 17855664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vitamin D receptor gene polymorphisms: analysis of ligand binding and hormone responsiveness in cultured skin fibroblasts.
    Gross C; Musiol IM; Eccleshall TR; Malloy PJ; Feldman D
    Biochem Biophys Res Commun; 1998 Jan; 242(3):467-73. PubMed ID: 9464239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.